Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of a Vero cell-derived whole-virus H5N1 influenza vaccine in healthy infants, children and adolescents
2009-013105-34Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of prepandemic influenza vaccine (h5n1) (whole virion, inactivated, prepared in cell culture) in Influenza A H5N1 infection (H5N1) and influenza pandemic, sponsored by Baxter International Inc. Primary endpoints: Systemic reactions within 7 days after first vaccination and Overall safety and tolerability. Started Jul 2009; status: completed.
02
Drugs
prepandemic influenza vaccine (h5n1) (whole virion, inactivated, prepared in cell culture)
03
Conditions
Influenza A H5N1 infection (H5N1)influenza pandemic
Beyond the preview
Go deeper on 2009-013105-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013105-34.